1. Home
  2. ENTO vs SGD Comparison

ENTO vs SGD Comparison

Compare ENTO & SGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTO
  • SGD
  • Stock Information
  • Founded
  • ENTO 2014
  • SGD 2021
  • Country
  • ENTO United States
  • SGD United States
  • Employees
  • ENTO N/A
  • SGD N/A
  • Industry
  • ENTO Biotechnology: Pharmaceutical Preparations
  • SGD
  • Sector
  • ENTO Health Care
  • SGD
  • Exchange
  • ENTO Nasdaq
  • SGD Nasdaq
  • Market Cap
  • ENTO 2.9M
  • SGD 2.6M
  • IPO Year
  • ENTO 2016
  • SGD N/A
  • Fundamental
  • Price
  • ENTO $0.49
  • SGD $1.28
  • Analyst Decision
  • ENTO
  • SGD
  • Analyst Count
  • ENTO 0
  • SGD 0
  • Target Price
  • ENTO N/A
  • SGD N/A
  • AVG Volume (30 Days)
  • ENTO 68.7K
  • SGD 209.2K
  • Earning Date
  • ENTO 11-13-2024
  • SGD 01-01-0001
  • Dividend Yield
  • ENTO N/A
  • SGD N/A
  • EPS Growth
  • ENTO N/A
  • SGD N/A
  • EPS
  • ENTO N/A
  • SGD N/A
  • Revenue
  • ENTO N/A
  • SGD $173,188.00
  • Revenue This Year
  • ENTO N/A
  • SGD N/A
  • Revenue Next Year
  • ENTO N/A
  • SGD N/A
  • P/E Ratio
  • ENTO N/A
  • SGD N/A
  • Revenue Growth
  • ENTO N/A
  • SGD N/A
  • 52 Week Low
  • ENTO $0.19
  • SGD $1.26
  • 52 Week High
  • ENTO $9.35
  • SGD $53.80
  • Technical
  • Relative Strength Index (RSI)
  • ENTO 43.83
  • SGD 33.74
  • Support Level
  • ENTO $0.45
  • SGD $1.33
  • Resistance Level
  • ENTO $0.54
  • SGD $1.46
  • Average True Range (ATR)
  • ENTO 0.06
  • SGD 0.16
  • MACD
  • ENTO 0.00
  • SGD 0.01
  • Stochastic Oscillator
  • ENTO 24.31
  • SGD 3.74

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

About SGD Safe and Green Development Corporation

Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe & Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partner with third-party equity investors or other developers.

Share on Social Networks: